Trial of Decompressive Craniectomy for Traumatic Intracranial Hypertension
NEJM 375:1119-1130,1183, Hutchinson, P.J.,et al, 2016
Willful Modulation of Brain Activity in Disorders of Consciousness
NEJM 362:579-589,648, Monti,M.M.,et al, 2010
Media Coverage of the Persistent Vegetative State and End-of-Life Decision-Making
Neurol 71:1027-1032,964, Racine,E.,et al, 2008
Terminating Artificial Nutrition and Hydration in Persistent Vegetative State Patients
Neurol 66:1624-1628, Larriviere,D &Bonnie,R.J., 2006
Persistent Vegetative State in Alzheimer Disease
Arch Neurol 54:1382-1384, Volicer,L.,et al, 1997
Physicians'Attitudes about the Care of Patients in the Persistent Vegetative State:A National Survey
Ann Int Med 125:104-147, Payne,K.,et al, 1996
Brain Death Occurs only with Destruction of the Cerebral Hemispheres and the Brain Stem
Arch Neurol 49:569-570, 5721992., Bernat,J.L., 1992
The First Seizure and Its Management in Adults and Children
BMJ 332:339-342, Pohlmann-Eden,B.,et al, 2006
Patent Foramen Ovale Management for Secondary Stroke Prevention:State-of-the-Art Appraisal of Current Evidence
Stroke 55:236-247, Sposato,L.A.,et al, 2024
Primary Diffuse Leptomeningeal Melanocytosis, A Diagnoatic Conundrum
Neurol 101:e576-3580, Selvarajan,J.M.P.,et al, 2023
Haloperidol for Treatment of ICU Delirium - Progress or Setback?
NEJM 387:2464-2465, Marcantonio,E.R., 2022
Five-Year Outcomes of PFO Closure or Antiplatelet Therapy for Cryptogenic Stroke
NEJM 384:970-971, , 2021
US Case Reports of Cerebral Venous Sinus Thrombosis with Thrombocytopenia after Ad26.COV2.S Vaccination, March 2 to April 21, 2021
JAMA 325:2448-2456,2445, See, I.,et al, 2021
Practice Advisory Update Summary: Patent Foramen Ovale and Secondary Stroke Prevention
Neurol 94:876-885, Messe, S.R.,et al, 2020
Tailoring the Approach to Embolic Stroke of Undetermined Source
JAMA Neurol 76:855-861, Kamel, H.,et al, 2019
Neurological Manifestations Among US Government Personnel Reporting Directional Audible and Sensory Phenomena in Havana, Cuba
JAMA 319:1125-1133, 1098, 1079, Swanson, R.L.,et al, 2018
PFO Closure for Cryptogenic Stroke
NEJM 378:1639-1642, Mi, M.Y.,et al, 2018
Patent Foramen Ovale Closure, Antiplatelet Therapy or Anticoagulation Therapy Alone for Management of Cryptogenic Stroke?
BMJ 362:k2515, Kuijpers, T.,et al, 2018
Ethical, Palliative, and Policy Considerations in Disorders of Consciousness
Neurol 91:471-475, Fins, J.J. & Bernat, J.L., 2018
Cardiac Magnetic Resonance Imaging: A New Tool to Identify Cardioaortic Sources in Ischaemic Stroke
JNNP 88:31-37, Yaghi, S.,et al, 2017
Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke
NEJM 377:1022-1032,1006,1093, Saver, J.L.,et al, 2017
Patent Foramen Ovale Closure or Anticoagulation Vs. Antiplatelets after Stroke
NEJM 377:1011-1021,1006,1093, Mas, J.L,et al, 2017
Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke
NEJM 377:1033-1042,1006,1093, Sondergaard, L.,et al, 2017
Hydrocephalus in Children
Lancet 387:788-799, Kahle, K.T.,et al, 2016
Closure Versus Medical Therapy for Preventing Recurrent Stroke in Patients with Patent Foramen Ovale and a History of Cryptogenic Stroke or Transient Ischemic Attack
Stroke 47:e188-e189, Li, J.,et al, 2016
Review of the Utility of Prophylactic Anticonvulsant Use in Critically Ill Patients with Intracerebral Hemorrhage
Stroke 47:2666-2672, Gilmore, E.J.,et al, 2016
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
NEJM 368:1092-1100,1152, Carroll, J.D.,et al, 2013
Percutaneous Closure of Patent Foramen Ovale in Cryptogenic Embolism
NEJM 368:1083-1091,1152, Meier, B.,et al, 2013
An Index to Identify Stroke-Related vs Incidental Patent Foramen Ovale in Cryptogenic Stroke
Neurol 81:619-625,619, Kent, D.M.,et al, 2013
Patent Foramen Ovale and Cryptogenic Stroke
Stroke 44:2676-2678, Furlan, A.J. and Jauss, M., 2013
Closure or Medical Therapy for Cryptogenic Stroke with Patent Foramen Ovale
NEJM 366:991-999,1048, Furlan,A.J.,et al, 2012
Seizure risk with AVM Treatment or Conservative Management
Neurol 79:500-507, Josephson, C.B.,et al, 2012
Pharmaceutical Interventions for Emotionalism After Stroke
Stroke 41:e460-e461, Hackett,M.L., et al, 2010
Botulinum Toxin Type A for the Treatment of Headache: Why We Say Yes
Arch Neurol 65:146-149,151, Ashkenazi,A. &Silberstein,S., 2008
Headache Therapy With Botulinum Toxin: Form Over Substance
Arch Neurol 65:149-151,151, Pakalnis,A. &Couch,J., 2008
Invited Article: Changing Concepts in Parkinson Disease: Moving Beyond the Decade of the Brain
Neurol 70:1996-2003, Marras,C. &Lang,A., 2008
Agitation and Delirium at the End of Life
JAMA 300:2898-2910,2929, Breitbart,W. &Alici,Y., 2008
Management of Antiphospholipid Antibody Syndrome, A Systematic Review
JAMA 295:1050-1057, Lim,W.,et al, 2006
Transient Global Amnesia: Increasing Evidence of a Venous Etiology
Arch Neurol 63:1334-1336 ,1336, Menendez,M. &Rivera,M.M., 2006
Cerebral Aneurysms
NEJM 355:928-939, Brisman,J.L.,et al, 2006
Simultaneous Carotid Endarterectomy and Coronary Artery Bypass Surgery in Canada
Neurol 64:1435-1437,1332, Hill,M.D.,et al, 2005
Thrombosis of the Cerebral VEins and Sinuses
NEJM 352:1791-1798, Stam,J., 2005
Patent Foramen Ovale Closure Devices
JAMA 294:366-369, Maisel,W.H.&Laskey,W.K., 2005
Patent Foramen Ovale in Young Adults with Unexplained Stroke
NEJM 353:2361-2372, Kizer,J.R. &Devereux,R.B., 2005
Potassium Channel Antibody-Associated Encephalopathy: A Potentially Immunotherapy-Responsive Form of Limbic Encepahlitis
Brain 127:701-712, Vincent,A.,et al, 2004
Analgesic Use: A Predictor of Chronic Pain and Medication Overuse Headache
Neurol 61:160-164,154, Zwart,J.-A.,et al, 2003
Management of Acute Optic Neuritis
Lancet 360:1953-1962, Hickman,S.J.,et al, 2002
Atrial Fibrillation and Stroke
Stroke 32:803-808, Hart,R.G. &Halperin,J.L., 2001
Intraspinal Steroids: History, Efficacy, Accidentality, and Controversy with Review of United States Food and Drug Administration Reports
JNNP 70:433-443, Nelson,D.A. & Landau,W.M., 2001